Ionis Completes Patient Enrollment in Phase 1/2a Trial of Ionis-HTTRx for Huntington’s Disease
Jun 27, 2017 06:48 am | Carolina Henriques
Ionis Pharmaceuticals has completed enrollment of the Phase 1/2a study evaluating the safety, tolerability, properties and movement within the body of Ionis-HTTRx in patients with Huntington’s disease (HD). Patients who complete the randomized, placebo-controlled, dose escalation study (NCT02519036) will be eligible to enroll in an open-label extension trial that should begin in the next few […]
The post Ionis Completes Patient Enrollment in Phase 1/2a Trial of Ionis-HTTRx for Huntington’s Disease appeared first on Huntington's Disease News.